Method of Differentially Diagnosing Dementias

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a method for distinguishing between various forms of dementia—including vascular dementia, frontotemporal lobe degeneration (FTLD), and others—by measuring the concentration of specific carboxy-terminally truncated amyloid beta peptides (Aβ1-37, Aβ1-38, and Aβ1-39) in patient body fluids such as blood or cerebrospinal fluid. The method uses these peptide biomarkers to improve the accuracy of differential diagnosis, helping to distinguish between types of dementias that often present with similar clinical symptoms.

Use CasesContent extracted from patent full text and abstract with AI.

• Clinical diagnosis in neurology practices to differentiate vascular dementia, frontotemporal dementia, and Alzheimer's disease.
• Routine screening in memory clinics evaluating patients with cognitive impairment.
• Pharmaceutical clinical trials, for selecting and stratifying dementia subtypes among participants.
• Laboratory test kits development for targeted dementia diagnosis.
• Research settings investigating the biochemical differences among dementias.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables more accurate and reliable differential diagnosis of dementia subtypes, especially between vascular dementia, FTLD, and Alzheimer's disease.
• Allows for minimally invasive testing, often using blood plasma instead of cerebrospinal fluid.
• Facilitates earlier and more appropriate treatment choices tailored to a patient's specific dementia type.
• May help avoid misdiagnosis and consequent inappropriate therapies.
• Supports the development of standardized laboratory kits for broad clinical use.
• Can enhance understanding and classification of various dementias in research and clinical settings.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

In an ex vivo method of differentially diagnosing dementias which include vascular dementias and/or frontotemporal lobe degenerations at least one carboxy-terminally truncated amyloid ß peptide selected from the group consisting of Aß1 -38, Aß1-37 and Aß1-39 is used as a biomarker in a body fluid of a patient.